NST doses first patient in Phase 2b clinical study of icosabutate in NASH (‘ICONA’)

25 Sep 2019

NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory and fibrotic diseases, today announces dosing of the first patient with...

FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019

23 Sep 2019

Ghent, Belgium, 23 September 2019 – Confo Therapeutics, a pioneering biopharma company, today announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology...

NorthSea Therapeutics strengthens its management team with the appointment of Mats Blom as CFO

4 Sep 2019

Naarden, The Netherlands, 4 September 2019 – NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic, inflammatory and fibrotic diseases, today announces the appointment of...

Cristal Therapeutics appoints Dr Werner Cautreels as a new Director and Board Chairman and Andre Verwei as Chief Financial Officer

1 Aug 2019

Maastricht, The Netherlands, 1st August 2019 – Cristal Therapeutics, a Phase 2 clinical stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announces that Dr Werner Cautreels is...

Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds

4 Jul 2019

Ghent, Belgium, and Dresden, Germany – 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR). The collaboration will combine...

Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication

20 Jun 2019

Ghent, Belgium, 20 June 2019 – Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and will support one of the...